Affordable and Effective Pharma Treatment
RMDM Pharma is the pharmaceutical wing of the RMDM Group.
It provides the third link in our comprehensive three-pronged approach to preventing, detecting and treating cancer.
Currently in the early stages, our team is conducting clinical trials for the release of a prodrug that renders current cancer treatments more effective.
Developed and patented by Dr. Johannes Coy and his team in Germany, this pro-drug – Oxybenfothiamine – hinders the activity of TKTL1 and decelerates the metabolisation of cancerous cells.
Combined with the early detection made possible by the Pantum Detect test, this affordable and effective treatment represents a paradigm shift in the treatment of cancer, allowing us to effectively fight even the most malignant and chemotherapy-resistant tumours.
Cutting-Edge Research Delivered to Local Markets
RMDM Pharma funnels this innovative research into local delivery throughout the UK and the Middle East and North Africa (MENA).
Please contact us should you like to know more about this pro-drug or if you would like to be informed of RMDM Pharma’s news and developments.
Other Resources You Might Find Useful
The UK’s Approach to Multi-Cancer Detection Tests
Last month, the UK National Screening Committee (UK NSC) shared their updated view on Multi-Cancer Detection (MCD) tests. They highlighted the potential and the immediate need for a multi-cancer detection solution in the UK. They are working to outline a roadmap for finding this solution. At RMDM, we are at…
Why Multi-Cancer Early Detection Tests are the Future
Historically, early detection has focused on routine screenings for only a handful of cancers, such as breast, colorectal, cervical, lung, and prostate cancers. However, these screenings are not always effective. Many cancers are still detected at later stages when treatment is less effective. This challenge has motivated scientists to develop…
The Problem with the Cancer Waiting Time Crisis
Last month the BBC revealed that “cancer waiting times for 2023 in England were the worst on record”. Only 64.1% of patients started treatment within 62 days of a cancer suspicion, meaning nearly 100,000 waited longer than they should for life-saving care. These numbers are not just another statistic, they…
The Effect of TKTL1 in Breast Cancer: A Biomarker for Early Detection
Breast cancer is the second leading cause of cancer-related deaths in women. Thanks to pioneering research and diagnostic tests, we are discovering solutions to detect breast cancer early on. The TKTL1 gene, in particular, represents an incredible leap in our understanding of metabolism and cancer cell growth. In a new…
Scientists transform breast cancer cells from treatment-resistant into treatment-sensitive
Scientists may have found a solution to treat an aggressive, treatment-resistant type of breast cancer. A new study suggests it is possible to change an aggressive type of breast cancer into a non-aggressive type that responds well to common treatments. Scientists discovered a way to sort through the intricate genetic…
Scotland’s £10 Million Investment to Improve Cancer Care
This week we are excited to share the news of an incredible commitment to early cancer detection by the Scottish Government. A £10 million fund has been granted to improve cancer waiting times. The fund will enable the NHS in Scotland to invest in staff skills, new diagnostic tests, and…
COVID-19 Hits Breast Cancer Screenings
Breast cancer is the most common cancer in the UK, with around 12,000 women diagnosed with the condition every year. Unfortunately, this week an analysis of NHS England figures by Cancer Research UK has found that around 10,600 fewer women started treatment for breast cancer in 2020, compared to the…
Cervical Cancer and the Need For Less Invasive Screening
Did you know 14th – 20th June 2021 is cervical screening awareness week? Cervical screening, also known as a smear test, is used to check the health of the cervix. It’s also the primary method used of detecting abnormal cells early, before they develop into cancer. The current government guidelines recommend that…
Focus on Cancer Research: For Diagnosis and Treatment
In some parts of the world, May is National Cancer Research Month – a month dedicated to highlighting the importance of lifesaving research into the devastating group of diseases collectively called cancer. Cancer affects millions of people across the globe. Statistics show that in 2018, there were more than 17 million new…
Growing Cancer Diagnoses in the Middle East
This week we were shocked by news of a new study in the Middle East. This study has found that young people across the UAE and Saudi Arabia are four times more likely to be diagnosed with cancer than their counterparts in the U.K and United States. We know that cancer doesn’t…